Europe 2017

**Confidential**

September 2017
Disclosure

To the extent statements contained in this presentation are not descriptions of historical facts regarding Presbia PLC and its subsidiaries (collectively “Presbia,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends,” or “continue,” or the negative of these terms or other comparable terminology.

Forward-looking statements contained in this presentation include, but are not limited to, statements regarding: (i) the initiation, timing, progress and results of our clinical trials, our regulatory submissions and our research and development programs; (ii) our ability to advance our products into, and successfully complete, clinical trials; (iii) our ability to obtain pre-market approvals; (iv) the commercialization of our products; (v) the implementation of our business model, strategic plans for our business, products and technology; (vi) the scope of protection we are able to establish and maintain for intellectual property rights covering our products and technology; (vii) estimates of our expenses, future revenues, growth of operations, capital requirements and our needs for additional financing; (viii) the timing or likelihood of regulatory filings and approvals; (ix) our financial performance; (x) developments relating to our competitors and our industry; and (xi) statements regarding our markets, including the estimated size and anticipated growth in those markets. Various factors may cause differences between our expectations and actual results, including those risks discussed under “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2017 and those risks discussed under “Risk Factors” in other reports we may file with the Securities and Exchange Commission.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
Presbia Restores Near Vision

Presbia has developed a solution for presbyopia, an age related condition affecting people from approximately 40 years of age, to help restore near vision

- Safe, effective and minimally invasive surgical procedure
- Currently marketed in certain markets outside the United States
- Marketed to people with presbyopia who need reading glasses or contact lenses
Large, Underserved and Growing Commercial/Market Opportunity

1.9 Billion Presbyopes

Source: 2016 Market Scope Refractive Surgery Report
The Presbia Flexivue Microlens™

- The Presbia Flexivue Microlens™ is a best in class treatment option for presbyopia

- A powered corneal inlay is implanted in the non-dominant eye, with minimal impact to binocular distance vision

Presbia has unique competitive advantages

- A refractive lens like reading glasses

- Designed to be removable

- The only option that is adjustable as you age (replace to a higher power)

- Can easily be done before or after LASIK or cataract surgery
The Presbia Procedure

10-Minute Procedure Utilizing Existing Femtosecond Laser

- True "Microlens" with 3.2 mm diameter and edge thickness of 0.015 mm
- Hydrophilic acrylic material similar to that used in IOLs for > 20 years
- Invisible to the naked eye once implanted
- Can be done concurrently or pre/post LASIK or cataract surgery
- Offered in a wide range of powers ranging from +1.5 diopter to +3.5 diopter, in 0.25 diopter increments

Femtosecond Laser
Creates a pocket in patient’s cornea

Lens Insert
Surgeon uses inserter to implant lens in patient’s cornea

Self-Sealing Pocket
Pocket self-seals, holding lens in place at center of visual axis
Corneal inlays are an exciting surgical treatment for presbyopia.
There are two primary competitors in the corneal inlay space.

**AcuFocus - KAMRA**

- Non-powered “disc” implanted in the non-dominant eye
- Utilizes the “pinhole effect” to focus light to enhance near vision
- The disc is visible to naked eye in light colored eyes
- Difficult for patient in low light environments
- Obstructs the view of the retina in diagnostic exams and cataract surgery
- Requires capital outlay from physician for “centration” equipment

**Revision Optics - Raindrop**

- Hydrogel placed under a LASIK-like flap in the non-dominant eye
- Changes the curvature of the cornea by adding volume under the flap
- Non-powered
- Challenging to remove
The Physician Appeal

No established surgical market for the 40–60 year old patient pool

Presbyopia

Presbia provides ophthalmologist with an exciting new option to treat patients with presbyopia

- Incremental revenue driver
- No capital expenditure required
- Short 10-minute procedure, short learning curve
- Private pay
Corneal inlay has the potential to impact the Presbyopia market similar to LASIK’s impact on vision correction in younger patients

- Grew **1230%** in the first 5 years of US commercialization – to over **1.2 million** procedures annually
- Steady state is about **2.8 million** procedures per year in North America, Europe and Asia
- Internal survey of 143 LASIK patients indicate **75%** would use a surgical solution to eliminate reading glasses

Positive takeaways from LASIK market:

- Rapid commercial acceptance of cash pay medical procedure to eliminate glasses
- Presbia Flexivue Microlens™ requires a less invasive procedure
- Serves early adult demographic, which is now approaching the age at which near vision deteriorates
- About 1.6x more people suffer from presbyopia than the conditions that LASIK treats (myopia, astigmatism, and hyperopia)

* Market Scope, 2014
Focused Commercial Strategy

• Build global KOL acceptance carrying momentum into US commercial launch

• Registered to commercialize in 42 different countries

• Clinics implanting in South Korea, Germany, Ireland, UK, Netherlands, Australia/NZ, and Canada

• Gain FDA approval and begin marketing in the United States

• Adjust marketing strategy to differentiate Presbia Flexivue Microlens™ from corneal inlay competitors
Compelling Results

Subjects can perform almost all near vision tasks without glasses.

For example, an improvement from reading a subhead in the newspaper (12pt font) to reading the content label (4pt font) on a medicine bottle.
Improvement in Uncorrected Near Visual Acuity in Operated Eyes

Average Uncorrected Near Visual Acuity in Operated Eyes
US Data (100% of Cohort up to Month 18)

- Preoperative
- Day 1
- Week 1
- Month 1
- Month 3
- Month 6
- Month 12
- Month 18

Average Uncorrected Near Visual Acuity (logMAR) - Operated Eye

~20/80
0.59
0.40
0.20
0.16
0.13
0.13
0.13
0.13

+5 line improvement in Uncorrected Near Visual Acuity in treated eyes compared to preoperative visual acuity

~20/25

CAUTION - Investigational Device. Limited by Federal (or United States) law to investigational use.
No change in Binocular Uncorrected Distance Visual Acuity

≥ 96% of Subjects with Uncorrected Distance Visual Acuity Preoperatively and at Month 18 between 20/16 and 20/25

Uncorrected Distance Visual Acuity in Both Eyes
US Data (100% of Cohort up to Month 18)

-0.10 to 0.16 logMAR (20/16 to 20/25)
0.18 to 0.38 logMAR (20/30 to 20/40)
0.40 logMAR (20/50 or worse)

<table>
<thead>
<tr>
<th>% of Subjects</th>
<th>Preoperative</th>
<th>Month 1</th>
<th>Month 3</th>
<th>Month 6</th>
<th>Month 12</th>
<th>Month 18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncorrected</td>
<td>98</td>
<td>97</td>
<td>98</td>
<td>99</td>
<td>98</td>
<td>96</td>
</tr>
<tr>
<td>Distance</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Visual Acuity</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

20/16 to 20/25

≥ 96% of Subjects with Uncorrected Distance Visual Acuity Preoperatively and at Month 18 between 20/16 and 20/25
US Registration Timeline

- Complete 24 Month follow up for 300 subjects
- Complete 24 Month follow up for ALL subjects
- Complete documents for PMA Module 4 (study report, labeling)

- Q4 2017
- Q1 2018
- Q2 2018
- Q3/4 2018

Submit PMA

Anticipate Approval

US PMA
### Business Highlights

#### Large, Underserved Presbyopia Opportunity
- 118 million presbyopes in the U.S.; 1.9 billion presbyopes worldwide (2016)*

#### Developed Ophthalmic Surgery Market
- Over 4,000 global ophthalmic surgery centers with no effective treatment of presbyopia†
- We believe ophthalmic surgeons are highly motivated to develop this market to replace lost LASIK volumes and utilize installed base of expensive femtosecond lasers

#### Best-in-Class Microlens Technology
- Refractive corneal inlay restores reading vision—on average 5 lines of improvement which is the highest reported UNVA change‡
- Wide range of lens size refractive powers to offer patients a customized therapy—competitors offer single size
- Compatible with additional diagnostic and surgical procedures (e.g. cataract surgery)—competitors are not§

#### FDA Pathway
- CE-marked, 1000+ lenses implanted globally
- Ongoing U.S. pivotal trial targeting FDA approval Q3 2018

#### Strong Leadership and Compelling Business Model
- Senior ophthalmic and global medical device experience; major KOLs worldwide supporting Presbia
- Compelling surgery center economics: 100% private pay, ~10 minute procedure time, leverage large installed base of femtosecond lasers
- Irish domicile

---

*Source: Market Scope 2016
†Source: Market Scope 2013
‡FDA Submission data
§OUS Data non-concurrent
freedom in sight™

CAUTION - Investigational Device. Limited by Federal (or United States) law to investigational use.